MarketPulse

neuro-ophthalmology

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis Eyes Clinical Inflection Point With Six Pivotal Readouts Ahead

Oculis plans March 2026 investor conferences highlighting six pivotal clinical readouts, including Privosegtor's breakthrough optic neuritis program and OCS-01 Phase 3 results expected Q2 2026.
OCSOCSAWinvestor conferencesclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis Charts Bold 2026 Path With Pipeline Milestones at Investor Conferences

Oculis announces March 2026 investor conference participation, showcasing pipeline advances including Privosegtor's optic neuritis breakthrough designation and anticipated Phase 3 readouts.
OCSOCSAWinvestor conferencesclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis Names Veterans Legal Executive as CLO Amid Clinical Pipeline Expansion

Oculis appoints seasoned legal executive Katie Kazem as Chief Legal Officer to strengthen governance as it advances clinical pipeline with late-stage therapeutic candidates.
OCSOCSAWsecurities lawclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Oculis Names Experienced Life Sciences Attorney as Chief Legal Officer

Oculis appoints Katie Kazem as Chief Legal Officer. She brings 15+ years of life sciences legal expertise to support the company's three late-stage clinical programs.
OCSOCSAWsecurities lawclinical trials